NIH Reporter #5U01NS123252-04

NIH Solicitation: Research on Antiglutamatergic Therapy for Neuroprotection Against Nerve Agents

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is seeking research proposals for antiglutamatergic therapies to protect the brain from nerve agents. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) - Products/Compounds for Study: - LY293558 - Caramiphen - Midazolam (as comparator) - Scope of Work: - Develop and evaluate antiglutamatergic therapies for neuroprotection - Test LY293558 and caramiphen in rat models - Compare efficacy to midazolam - Address neuroprotection in both adult and aged populations - Unique Requirements: - Focus on combination therapy (LY293558 + caramiphen) - Emphasis on efficacy in aged as well as adult animal models - Estimated Funding: - Approximately $721,888 - Period of Performance: - Two years

Description

This NIH grant opportunity seeks to develop and evaluate antiglutamatergic therapies aimed at protecting the brain against nerve agents. The project focuses on testing a combination of LY293558 and caramiphen in rat models, comparing their efficacy to existing treatments such as midazolam. The research targets neuroprotection in both adult and aged populations. The funding amount is approximately $721,888, with a project duration from September 2025 to August 2027.

View original listing